Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Device: tumor maker interval shortly
- Registration Number
- NCT01277653
- Lead Sponsor
- Yonsei University
- Brief Summary
There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used
- Detailed Description
There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1000
- LC
- previous HCC
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description tumor maker interval every 6 month tumor maker interval shortly tumor maker interval every 6 month
- Primary Outcome Measures
Name Time Method the difference of curative treatments & survival rates 4 years
- Secondary Outcome Measures
Name Time Method the difference of early detection rates of HCC between both groups 4 years
Trial Locations
- Locations (1)
Severance Hospital
🇰🇷Seoul, Seodaemun-gu, Korea, Republic of